01-27-2009: Bio Nano Consulting (BNC) has signed a collaborative agreement with a Top 5 pharma company to develop new assay systems for their product discovery and development. The agreement is the eighth major contract won by BNC in 2008, and follows the completion in mid December of a second contract with Targanta Therapeutics Corporation, in which BNC used cantilever-array assay system technology to analyse the mechanism of action of Targanta’s novel lipoglycopeptide antibiotic, oritavancin.
Commenting on the new contract, Dr David Sarphie, CEO of Bio Nano Consulting said, “Nanotechnology is finding more and more applications in industry, and BNC is developing a well-deserved reputation within the pharmaceutical, biotech, medtech and healthcare industries for providing novel approaches in research and development. With the unparalleled expertise of scientists at UCL’s London Centre for Nanotechnology, the Institute of Biomedical Engineering at Imperial College and the National Physical Laboratory, BNC is ideally placed to offer nanotechnology solutions in these sectors”.
Bio Nano Consulting (BNC) announced the availability of a new technique that screens low-yielding proteins, facilitating the evaluation of both protein denaturation and protein:drug interactions.
This novel method, pioneered by researchers from the UCL Department of Biochemical Engineerin ... more
Researchers at Bio Nano Consulting (BNC) have produced a miniaturized version of the London tube map, measuring only 2x3 mm - about the size of a pinhead. The map was etched using specialised lasers by Dr Richard Winkle, a BNC researcher at Imperial College London, whilst testing the capabi ... more
Bio Nano Consulting (BNC) has signed a collaborative agreement with a Top 5 pharma company to develop new assay systems for their product discovery and development. The agreement is the eighth major contract won by BNC in 2008, and follows the completion in mid December of a second contract ... more